Nicolet Bankshares Inc. Has $486,000 Holdings in Baxter International Inc (BAX)
Nicolet Bankshares Inc. decreased its holdings in shares of Baxter International Inc (NYSE:BAX) by 24.6% in the fourth quarter, HoldingsChannel reports. The firm owned 7,521 shares of the medical instruments supplier’s stock after selling 2,457 shares during the period. Nicolet Bankshares Inc.’s holdings in Baxter International were worth $486,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Acadian Asset Management LLC grew its holdings in shares of Baxter International by 156.7% during the fourth quarter. Acadian Asset Management LLC now owns 657,855 shares of the medical instruments supplier’s stock valued at $42,523,000 after buying an additional 401,532 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Baxter International by 35.8% during the third quarter. Canada Pension Plan Investment Board now owns 1,413,054 shares of the medical instruments supplier’s stock valued at $88,669,000 after buying an additional 372,500 shares during the last quarter. Segall Bryant & Hamill LLC grew its holdings in shares of Baxter International by 209.0% during the third quarter. Segall Bryant & Hamill LLC now owns 412,054 shares of the medical instruments supplier’s stock valued at $25,856,000 after buying an additional 278,685 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Baxter International by 619.2% during the third quarter. Nordea Investment Management AB now owns 188,842 shares of the medical instruments supplier’s stock valued at $11,850,000 after buying an additional 162,584 shares during the last quarter. Finally, AustralianSuper Pty Ltd purchased a new stake in shares of Baxter International during the third quarter valued at approximately $9,871,000. 83.54% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the sale, the senior vice president now owns 124,609 shares in the company, valued at $8,130,737.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 6.79% and a return on equity of 15.12%. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.77 billion. During the same quarter last year, the company posted $0.57 earnings per share. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. analysts expect that Baxter International Inc will post 2.78 EPS for the current fiscal year.
A number of equities research analysts have recently commented on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Tuesday, October 24th. BMO Capital Markets reiterated a “buy” rating and set a $70.00 price target on shares of Baxter International in a report on Friday, October 13th. Bank of America upgraded shares of Baxter International from a “neutral” rating to a “buy” rating in a report on Tuesday, January 2nd. Morgan Stanley increased their price target on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a report on Thursday, October 26th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $66.00 price target on shares of Baxter International in a report on Wednesday, November 22nd. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Baxter International currently has an average rating of “Buy” and a consensus target price of $69.86.
ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2018/02/06/nicolet-bankshares-inc-has-486000-holdings-in-baxter-international-inc-bax.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.